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Background: Achieving optimal outcomes in type 2 diabetes (T2DM) involves several demanding self-care
behaviours, e.g. managing diet, activity, medications, monitoring glucose levels, footcare. The Self-Care Inventory-
Revised (SCI-R) is valid for use in people with T2DM in the US. Our aim was to determine its suitability for use
in the UK.
Methods: 353 people with T2DM participated in the AT.LANTUS Follow-on study, completing measures of diabetes
self-care (SCI-R), generic and diabetes-specific well-being (W-BQ28), and diabetes treatment satisfaction (DTSQ).
Statistical analyses were conducted to explore structure, reliability, and validity of the SCI-R.
Results: Principal components analysis indicated a 13-item scale (items loading >0.39) with satisfactory internal
consistency reliability (α = 0.77), although neither this model nor any alternatives were confirmed in the
confirmatory factor analysis. Acceptability was high (>95% completion for all but one item); ceiling effects were
demonstrated for six items. As expected, convergent validity (correlations between self-care behaviours) was found
for few items. Divergent validity was supported by expected low correlations between SCI-R total and well-being
(rs = 0.02-0.21) and treatment satisfaction (rs = 0.29). Known-groups validity was partially supported with significant
differences in SCI-R total by HbA1c (≤7.5% (58 mmol/mol): 72 ± 11, >7.5% (58 mmol/mol): 68 ± 14, p < 0.05) and
diabetes duration (≤16 years: 67 ± 13, >16 years: 71 ± 12, p < 0.001) but not by presence/absence of complications
or by insulin treatment algorithm.
Conclusions: The SCI-R is a brief, valid and reliable measure of self-care in people with T2DM in the UK. However,
ceiling effects raise concerns about its potential for responsiveness in clinical trials. Individual items may be more
useful clinically than the total score.
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Optimal management of type 2 diabetes (T2DM)
involves a combination of self-care behaviours, e.g. regu-
lating carbohydrate, calorie, fat and alcohol intake; being
physically active; taking oral medications as recommended;
monitoring blood/urine glucose levels; checking feet.
These can be difficult lifestyle changes to make and sus-
tain. The progressive loss of beta-cell function means that
people with T2DM are likely to need insulin therapy at
some point to achieve and maintain optimal glycaemic
outcomes [1]. Despite the biomedical and psychological
advantages of adding insulin to the management regimen
[2], more than a quarter of people with T2DM would re-
sist the addition of insulin if prescribed [3] and 75% con-
sider initiating insulin a major crisis [4]. This is known as
‘psychological insulin resistance’, which can occur due to
fears of hypoglycaemia, weight gain or injections [5].
Many of these concerns and the overall burden of
self-care may be minimised with a simpler regimen of
a single daily injection, e.g. insulin glargine, which has
a longer duration of action, produces more pre-
dictable action profile [6], and reduces the risk of
hypoglycaemia [7]. Thus, the addition of insulin
glargine may add minimal burden to the already com-
plex treatment regimen.
As the vast majority of diabetes care is self-care,
performed by the person with diabetes and/or their fam-
ily/carers, clinicians and researchers need valid and reli-
able measures of self-care in order to:
– gain insight into the individual’s actual self-care
practices
– understand the individual’s barriers to achieving
optimal glycaemic outcomes
– understand the burden of self-care experienced and
how the individual copes with that burden
psychologically
– ensure that treatment is not intensified at a time
when the person with diabetes may be already
struggling to engage in effective self-care
– to evaluate the outcomes of new approaches to care,
e.g. the addition of insulin to the self-care regimen
Yet, there are a number of complexities to the valid
and reliable assessment of self-care behaviours and sev-
eral approaches exist. Clinicians sometimes use glycated
haemoglobin (HbA1c) as a proxy measure of self-care,
though it is an unreliable indicator of self-care [8]. Ob-
jective methods, such as observation (e.g. tablet counts
and pedometers), can be costly to implement in studies
and clinical practice, and are limited by the individual’s
propensity to improve behaviours when monitored [9].
Self-report is the most practical method of ascertaining
insights into self-care behaviours but can be subject tobias. The use of specific, nonjudgmental questions, asked
in a standardised format reduces the tendency to re-
spond in a socially desirable way [10]. Two commonly
used measures are the Summary of Diabetes Self-Care
Activities (SDSCA) [11], the Self-Care Inventory [12],
and the Self-Care Inventory-Revised [13]. The SDSCA
invites the respondent to self-report the frequency of
specific behaviours (e.g. “on how many of the last seven
days did you take your recommended diabetes medica-
tion?”) [11]. The critical issue is how to determine the
extent to which the self-report is an accurate reflection
of behaviour and engagement with the treatment
regimen. The latter is particularly pertinent as the
standardised assessment of self-care (i.e. using a ques-
tionnaire measure) does not fit easily with a condition
such as diabetes, in which each individual is likely to
have a different treatment regimen prescribed or is
encouraged to take an active role in regulating his/her
treatment, adopting a flexible approach (e.g. self-titration
rather than fixed insulin doses and mealtimes). Unlike
measures that assess the frequency of certain behaviours, the
Self-Care Inventory Revised (SCI-R) [9,10] does not presume
an “ideal” regimen or that all individuals have the same regi-
men. Rather, the SCI-R evaluates individuals’ perceptions of
how well they engage with their individualised treatment
recommendations.
The AT.LANTUS Follow-on study was conducted to
follow-up on those who successfully completed the AT.
LANTUS Type 2 trial [7] to determine how treatment of
their diabetes has evolved since the study finished (e.g.
whether or not they remain on glargine, and/or are self-
titrating or following a prescribed regimen) and how this
may have affected key biomedical and psychological
outcomes (e.g. HbA1c, severe hypoglycaemia, weight
control, self-care, treatment satisfaction and well-being).
Consequently, we needed a self-care measure that would
be suitable in the context of an individual’s unique treat-
ment regimen.
The original Self-Care Inventory (SCI) [12,14] has
been used in several US studies of T2DM [15,16]. Ne-
cessarily, measures of self-care need to be updated regu-
larly to maintain relevance to modern treatments and
technologies. A more recent study by Weinger and
colleagues revealed that the revised version (SCI-R;
modified to reflect current diabetes practice and to be
more suitable for adults rather than adolescents) is a
psychometrically sound measure of engagement with
recommended diabetes self-care behaviours of adults
with type 1 diabetes or T2DM in the US [13]. It has
been shown to have satisfactory internal consistency reli-
ability (α = 0.87), good evidence of concurrent validity
with the SDSCA measure of self-care (r = 0.63) and con-
struct validity, with low to moderate correlations with
measures of diabetes-related distress, depression, anxiety
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has been undertaken in the UK. Thus, the aim of the
present study was to undertake further psychometric
validation of the SCI-R for use in adults with T2DM in
the UK using data from the AT.LANTUS Follow-on
study.
Methods
Participants
The AT.LANTUS Type 2 study was based in the UK, in-
cluding approximately 600 participants from 137 centres
in the UK. Approval for the study was granted by the
Leicestershire, Northamptonshre and Rutland Research
Ethics Committee. Methods for the AT.LANTUS trial are
reported elsewhere [7]. For sites that agreed to participate
in the AT.LANTUS Follow-on study, participants who
completed the original trial were approached at clinic
visits or sent postal invitations and asked to complete and
return a form if they did not want to participate. After two
weeks, patients were contacted by telephone to check if
they had received the invitation and a visit was booked if
they wanted to participate. All participants completed the
questionnaires at the clinic during the study visit. A
total of 353 participants completed questionnaires and
provided biomedical data.
Biomedical outcomes
HbA1c is a measure of average blood glucose over the
past two-three months. An HbA1c was conducted at the
visit unless it had been recorded in the medical notes
within the past three months, in which case this figure
was used. HbA1c was analysed locally using DCCT
aligned methods.
Psychological outcomes
The Self-Care Inventory-Revised (SCI-R) [12,13] is a 15-
item self-report questionnaire assessing patients’ per-
ceptions of various self-care behaviours, i.e. diet (4
items), glucose monitoring (2 items), medication admin-
istration (3 items), exercise (1 item), low glucose levels
(2 items), preventative/routine aspects of care (3 items).
For people with T2DM it is recommended that three
items (checking ketones, adjusting insulin and wearing a
Medic Alert) are not scored [22]. Respondents rate their
own self-care on a 5-point Likert scale to reflect how
well they followed recommendations during the past
month (i.e. from “never” (scored as 1) to “always”
(scored as 5)). For scoring, items are averaged and
converted to a 0–100 point scale, with higher scores in-
dicating higher levels of self-care.
The Well-being Questionnaire – 28 items (W-BQ28)
[17] is an extended version of the widely used 12-item
generic version of the W-BQ [18]. It includes seven 4-
item subscales: Generic Negative Well-being, GenericPositive Well-being, Energy, Generic Stress, Diabetes-
specific Negative Well-being, Diabetes-specific Negative
Well-being and Diabetes-specific stress. Higher scores
indicate higher levels of the named aspect of well-being.
The Diabetes Treatment Satisfaction Questionnaire
(DTSQ) [19] includes eight items, six of which form a
scale (scored 0–36) in which higher scores indicate
greater treatment satisfaction. Two individual items
(scored 0–6) measure perceived frequency of hypergly-
caemia and hypoglycaemia. Higher scores indicate
greater perceived frequency.Psychometric analyses
Psychometric validation consists of a series of statistical
analyses to determine the acceptability, reliability, valid-
ity and responsiveness of a PRO measure. All statistical
analyses were performed using SPSS 16.0 or AMOS
16.0. Skewness and kurtosis statistics demonstrated non-
normal distributions, indicating use of non-parametric
statistical tests.
Acceptability was assessed by examining completion
rates and identifying floor and ceiling effects (i.e. >25%
scoring minimum/maximum response).
Reliability coefficients (Cronbach’s α) were calculated
for various computations of the SCI-R scale score (see
six models discussed below). A Cronbach’s alpha reliabil-
ity statistic of >0.70 is considered as the minimum ac-
ceptable criterion of internal consistency [20].
Content validity was assessed by confirmatory factor
analyses (CFA) on the structure of the SCI-R. Some of
the items are not necessarily suited to T2DM [13] or
would not necessarily be expected to contribute to over-
all self-care (in terms of predicting or correlating with
other outcomes, e.g. HbA1c). Thus, we evaluated several
combinations of items. Three unidimensional models
were tested (excluding various combinations of items) to
investigate whether the structure reported elsewhere
[13] could be replicated. Item 3 was excluded because it
was considered irrelevant to people with T2DM and was
completed by only 34% of respondents; item 13 was
excluded because wearing a medic alert is unlikely to be
associated with other self-care activities or HbA1c; item
15 was excluded because adjusting insulin was unlikely
to be relevant to all respondents. The two-factor models
were selected on the basis of conceptual relevance, with
the intention of identifying a subscale that would have a
good fit to the data and be capable of predicting self-
care outcomes, e.g. HbA1c. Multiple goodness of fit tests
were used to evaluate the fit between the six models and
the data [21]. A comparative fit index (CFI) [22] and
Tucker-Lewis index (TLI) [23] of ≥0.90 indicate a good
fit to the data [24], a root mean squared error of
approximation (RMSEA) value <0.08 indicate an
Khagram et al. Health and Quality of Life Outcomes 2013, 11:24 Page 4 of 9
http://www.hqlo.com/content/11/1/24acceptable fit to the data [24], while values <0.05 indi-
cate a good fit to the data [25].
Convergent validity was assessed by examining
Spearman’s rank correlations between the items of the
SCI-R. It was expected that there would be moderate
correlations (r = 0.3-0.5) between items. Strong correlations
were not expected as performing one self-care activity does
not necessarily mean another will be performed at a similar
level. Divergent validity was assessed by examining
Spearman’s rank correlations between the SCI-R and the
W-BQ28 and DTSQ. Weak correlations (r < 0.3) were
expected, as the SCI-R would not be expected to be
highly correlated to measures of well-being or treatment
satisfaction.
Known-groups validity was assessed by examining
differences (Mann Whitney U-test) in SCI-R total scores
duration of diabetes (median split), HbA1c (split at 7.5%
(58 mmol/mol), the maximum target recommended
[23]) and presence/absence of complications.
Interpretability can be informed by establishing min-
imal important differences (MIDs) and minimal clinic-
ally important differences (MCIDs) in mean scores, so
that the significance of changes in scores following inter-
vention or differences between groups can be under-
stood. The minimal important difference (MID) was
calculated using both a distribution-based approach (i.e.
defining the MID as 0.5 times the standard deviation)
and an anchor-based approach, using DTSQ scores (me-
dian split) serving as anchors for the SCI-R scores. An
anchor-based MCID was also calculated with HbA1c
(split at 7.5% (58 mmol/mol)).
Descriptive statistics are mean ± standard deviation
(SD) or (number %).Results
Descriptive data
Of the 353 participants, 137 (38.8%) were women, the
mean age was 65.6 ± 9.3 years, the mean duration of diabe-
tes was 16.6 ± 6.6 years and the mean HbA1c was 8.3 ±
1.4% (67 ± 16 mmol/mol) (Table 1). Almost one third
(104; 29.5%) had at least one long-term complication.Table 1 Demographic and biomedical characteristics (n = 353
Demographic n Mean SD
Age (years) 353 65.6 9.34
Duration of diabetes (years) 352 16.63 6.55
Current HbA1c (%) 352 8.31 1.39
Current HbA1c (mmol/mol) 352 67 16
Complications (n)a 352 1.36 1.24
SD (standard deviation).
aretinopathy, neuropathy, nephropathy, macroangiopathy, other vascular disorders.Acceptability of the SCI-R
Completion rates were high (>95%) for all items except
items 3 and 10. Substantial ceiling effects were apparent
for six items (Table 2).
Exploratory factor analyses
An unforced principle components analysis (PCA)
with varimax rotation produced 5 components with
eigenvalues >1. However, neither this nor subsequent
forced 4-, 3- and 2-factor models (not shown) produced
interpretable factors. For a 13-item forced one-factor so-
lution (items 3 and 13 excluded; Table 2), all items
loaded >0.4 on a single factor, except item 8 (keep food
records), which loaded 0.39. This item was retained in
the scale given its salience for the concept of self-care in
T2DM and its factor loading’s proximity to the accepted
threshold of 0.4.
Confirmatory factor analyses
Fit indices for the models tested using CFA are shown in
Table 3, with path diagrams shown in Additional file 1:
(Appendix 1). The model depicting the SCI-R as a 14-
item uni-dimensional scale (excluding item 3) did not
provide a good fit to the data. Thus, a number of add-
itional models were tested, each based upon theoretical
rationales for how the items of the SCI-R might be
expected to relate to each other and form scales. None
of the additional models evaluated offered a good fit to
the data.
Reliability analyses
For the 13-item scale (excluding items 3 and 13, based
upon the factor solution depicted in Table 2), Cronbach’s
alpha was satisfactory (α = 0.77). Item-total correlations
for the SCI-R ranged from r = 0.31 to r = 0.53 (Table 2).
Dealing with missing values
Where missing values exist, an SCI-R scale score can be
imputed as long as the scale remains reliable (i.e. α >
0.70) with fewer than 13 items contributing to the scale
score. The item contributing most to the reliability of
the 13-item SCI-R scale (i.e. with the lowest ‘alpha if)
Median Mode Min Max Range
66.0 70 18 92 74
15.91 16.85 5.88 41.73 35.85
8.00 8.00 5.80 13.90 8.10
64 64 40 128 88
1.00 .00 .00 5.00 5.00
Table 2 SCI-R: mean (SD), exploratory factor analysis, acceptability, internal consistency reliability (of uni-dimensional
Model 2 (13 items excluding 3 & 13)), and interpretability
SCI-R items
Mean
(standard
deviation)
Exploratory factor analysis Acceptability Reliability Interpretability
Forced one-
factor
solution1
Forced one-factor
solution1 (excluding
item 13)
Completion
rate N = 353
n (%)
%
floor
%
ceiling
Alpha Item-total
correlations
MID MCID
1. Check blood
glucose with
monitor
4.26 (0.94) 0.55 0.55 350 (99.2) 1.4 53.3 .75 .46 0.26 – 0.47 0.38
2. Record blood
glucose
3.86 (1.32) 0.45 0.45 343 (97.2) 8.2 45.3 .76 .35 0.34 – 0.66 0.34
3. Check ketones a 2.40 (1.68) - - 121 (34.2) - - - - - -
4. Correct dosage
of pills/insulin
4.81 0.57 0.52 0.54 343 (97.2) 1.1 82.7 .76 .36 0.07 – 0.28 0.05
5. Take pills/insulin
at correct time
4.60 0.63 0.55 0.56 348 (98.6) 0.8 64.0 .76 .38 0.19 – 0.31 0.19
6. Correct food
portions
3.77 0.80 0.66 0.67 349 (98.9) 1.7 15.3 .75 .51 0.39 – 0.40 0.08
7. Meals/snacks
eaten on time
3.92 0.83 0.69 0.69 348 (98.6) 1.7 22.1 .74 .53 0.29 – 0.42 0.31
8. Keep food
records
1.59 0.99 0.39 0.39 346 (98.0) 62.9 3.7 .76 .31 0.20 – 0.49 0.05
9. Read food labels 3.12 1.37 0.49 0.49 347 (98.3) 18.7 19.0 .76 .38 0.32 – 0.69 0.14
10. Recommended
carbohydrates
3.57 1.24 0.54 0.54 302 (85.6) 8.5 21.0 .75 .44 0.52 – 0.62 0.26
11. Carry quick
acting sugar
3.78 1.48 0.54 0.53 347 (98.3) 15.3 46.7 .75 .43 0.25 – 0.74 0.26
12. Attend clinic
appointments
4.86 0.48 0.57 0.57 347 (98.3) 0.6 87.8 .76 .42 0.10 – 0.24 0.13
13. Wear medic
alert
2.15 1.71 0.25 - 348 (98.6) 65.4 22.1 - - 0.15 – 0.85 0.14
14. Exercise 3.35 1.09 0.52 0.52 349 (98.9) 5.4 17.0 .75 .40 0.26 – 0.54 0.08
15. Adjust insulin
dosage
3.38 1.42 0.42 0.42 338 (95.8) 17.0 24.9 .76 .35 0.06 – 0.71 0.04
SCI-R Total Score b 69.00 12.82 348 (98.6) - - .77 - 6.50 – 7.0 4.00
aAs so few respondents completed item 3, this item was excluded from the overall analyses.
bSCI-R Total Score = sum of 13 items (excluding items 3 and 13).
MID: minimal important difference; MCID: minimal clinically important difference.
Table 3 Model fit of the SCI-R
Model1 χ2 (DF) CFI TLI RMSEA
1: unidimensional, 14 items (excluding item 3) 412.49** (77) .663 .602 .111
2: unidimensional, 13 items (excluding items 3 and 13) 385.36** (65) .670 .670 .118
3: unidimensional, 12 items (excluding item 3, 13 & 15) 349.02** (54) .677 .605 .125
4: 2-factor model (active-management & preventative routine), 15 items (including item 3) 427.50** (89) .662 .601 .104
5: 2-factor model (glycemic control & other items), 15 items (including item 3) 429.53** (89) .660 .599 .104
6: 2-factor model (glycemic control & other items), 13 items (excluding items 3 & 13) 385.36** (64) .669 .597 .119
** p < 0.001.
1As recommended by Weinger et al. (2005) and indicated by substantial missing data, item 3 (check ketones) was excluded from our initial testing of
unidimensional models. However, as many people had completed item 3, we tested its inclusion in models 4 and 5.
DF, degrees of freedom, CFI, comparative fit index, TLI, Tucker-Lewis index, RMSEA, root mean squared error of approximation.
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Table 5 Divergent validity (Correlation of SCI-R with
DTSQ & W-BQ28)
SCI-R total
DTSQ: Total Score .285**
DTSQ: Perceived frequency of hyperglycaemia -.055
DTSQ: Perceived frequency of hypoglycaemia .089
W-BQ28: Generic Negative Well-Being -.139**
W-BQ28: Generic Positive Well-Being .188**
W-BQ28: Generic Stress -.179**
W-BQ28: Energy .020
W-BQ28: Diabetes-Specific Negative Well-Being -.114
W-BQ28: Diabetes-Specific Positive Well-Being .206**
W-BQ28: Diabetes-Specific Stress -.173**
W-BQ28: W-BQ12 scale .170**
W-BQ28: W-BQ16 scale .214**
W-BQ28: Generic W-BQ12 scale .213**
W-BQ28: Diabetes-Specific W-BQ12 scale .211**
*p < 0.05, ** p < 0.01 (Spearman Rank correlations).
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that even if respondents did not complete the ‘best item’,
reliability would remain acceptable. Thus, item 7 was
removed and the analysis re-run. The item that
contributed most to the reliability of a 12-item SCI-R
was item 1 (α = 0.718) demonstrating that the reliability
again remained acceptable. Thus, item 1 was removed
and the analysis re-run. Item 10 (α = 0.688) contributed
most to the reliability of an 11-item SCI-R scale, indicat-
ing that reliability would fall below acceptable levels (i.e.
α = 0.7) if it were removed (and/or only 10 items were
complete). Thus, the SCI-R total score remains reliable
if the respondent has completed 11 or more of the 13
items. Further analyses using the SCI-R total score were
conducted where respondents completed 11 or more of
the 13 items (n = 348).
Convergent and divergent validity
The convergent validity of the SCI-R was not supported;
the highest correlation was observed between ‘recording
blood glucose’ (item 2) and ‘checking blood glucose with
a monitor’ (item 1), while the majority of the remaining
items produced either low correlations or none at all
(Table 4). Divergent validity was supported with
expected low correlations observed between SCI-R total
and W-BQ28 subscales/scales (rs = 0.02-0.22) and DTSQ
total (rs = 0.29) (Table 5).
Known-groups validity
Known-groups validity was supported partially with sig-
nificant differences in SCI-R total by HbA1c (≤7.5% (58 -
mmol/mol): 72 [11], >7.5% (58 mmol/mol): 68 [14], p <
0.05) and diabetes duration (≤16 years: 67 [13], >16 years:
71 [12], p < 0.001). No significant differences in the totalTable 4 Convergent validity: correlation between SCI-R items
SCI-R SCI-R total 1 2 4
1. Check blood glucose with monitor .523**
2. Record blood glucose .504** .566**
4. Correct dosage of pills/insulin .320** .150** .190**
5. take pills/insulin at correct time .284** .157** .114* .473**
6. Correct food portions .491** .194** .112* .148**
7. Meals/snacks eaten on time .509** .250** .210** .163**
8. Keep food records .429** .156** .179** .146**
9. Read food labels .545** .111* .102 .147**
10. Recommended carbs .636** .221** .207** .215**
11. Carry quick acting sugar .552** .179** .129* .166**
12. Attend clinic appointments .275** .234** .164** .254**
13. Wear medic alert .171** .112* .083 .067
14. Exercise .472** .077 .034 .120*
15. Adjust insulin dosage .488** .190** .090 -.092score or any SCI-R items were found between presence/
absence of complications or by treatment algorithm
(Additional file 1: Appendix 2).
Interpretability
Table 2 indicates the MID range and MCID for each
item and total score of the SCI-R. The MCID was
established as 4.00, indicating that a difference in total
score (e.g. between groups or following intervention) of
≥4 points would be clinically significant. Using distribu-
tion and anchor-based approaches, a more conservative
MID was established, requiring a difference of ≥6.5
points to be considered important. Table 2 shows the& SCI-R total score
5 6 7 8 9 10 11 12 13 14
.147**
.215** .529**
.092 .132* .163**
.100 .299** .210** .225**
.218** .382** .392** .144* .307**
.056 .133* .198** .135* .256** .304**
.173** .077 .152** .045 .055 .194** .220**
.050 .023 .114* .052 .134* .045 .248** .087
.095 .204** .125* .160** .174** .214** .242** .130* .056
.024 .151** .124* .146** .128* .208** .209** .105 .103 .264**
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reflecting uncertainty for the significance of differences
for individual scores.
Discussion
This study examining the preliminary psychometric prop-
erties of the SCI-R in adults with T2DM in the UK
demonstrated evidence supporting its structure, reliability,
divergent validity and known groups validity. Although a
uni-dimensional scale could not be confirmed using CFA,
exploratory analyses supported a 13-item uni-dimensional
scale (with satisfactory reliability), consistent with the
findings of the US validation [13]. The internal consistency
of the 13-item unidimensional scale was satisfactory, and
also consistent with the US validation.
Despite identifying a general factor from which a total
score can be computed, the lack of convergent validity
for the majority of items indicates that they are relatively
disparate, confirming previous findings that different
aspects of self-care do not correlate highly [26,27], and
reflecting the multidimensional nature of diabetes self-
care [11].
Indeed, a range of independent behaviours are
required for optimal self-management and individuals
may choose to undertake certain self-care activities with-
out necessarily taking on others. For example, an indi-
vidual may record blood glucose results diligently but
not think it an important part of his/her self-
management to read food labels. This may be due to
some aspects of self-care being more/less consistent with
others, the value/emphasis placed on each activity by
healthcare providers or reflect the variable ease/difficulty
of incorporating various self-care behaviours into one’s
routine on a regular basis. As has been found with
knowledge [28], scores for individual aspects of self-care
activities may be more predictive of various outcomes
(e.g. HbA1c) than the total score. In light of these findings
(and mixed support for a uni-dimensional scale), we rec-
ommend that SCI-R items are scored individually as well
as summed to form a total score for some purposes.
Despite our findings that uni-dimensionality may not
be necessary (or expected) when assessing self-care
behaviours in T2DM, the responsiveness (or sensitivity
to change) of individual items may be an issue. Like
other measures of self-care behaviour [11], many items
were prone to ceiling effects, which may be a factor of
some aspects of self-care being easier or considered
more important than others to undertake consistently.
This was not reported in the US validation despite simi-
lar total scores but the SCI-R was found to be responsive
following a psychological or cholesterol-intensive inter-
vention [13]. One of the challenges of using self-report
measures of self-care is that they are likely to be prone
to social desirability bias (i.e. the individual’s naturaltendency to respond to items in a way that he/she
believes others would value). Despite being cost-effective
and practical, self-report of self-care behaviours is
considered by many to be problematic for this very rea-
son. Tools are available to assess the individual’s ten-
dency to respond in socially desirable ways [29,30] but
we were unable to use those in the context of our study
and they may not be practical in most research or clin-
ical practice scenarios.
Another challenge facing investigators is determining the
significance of any observed change in scores, as statistical
significance can often be achieved with large sample sizes.
Furthermore, when working clinically, it is not possible to
ascertain the statistical significance of a difference between
scores at two consecutive consultations for a single patient.
In response to this challenge, the minimal clinically im-
portant difference (MCID) is a statistical technique that
can be defined as “the smallest difference in score in the
domain of interest which patients perceive as beneficial
and which would mandate, in the absence of troublesome
side effects and excessive cost, a change in the patient’s
management” [31]. The FDA’s draft guidance on the use of
patient-reported outcome measures in support of labeling
claims [32] encouraged developers and researchers to iden-
tify a MID or MCID as a benchmark for interpreting the
clinical importance or relevance of study results to patients
– though the more recent definitive guidance has omitted
this recommendation [33]. In this UK study, the MCID for
the SCI-R total scale was established for the first time, indi-
cating that a minimum change of four points would be
required for the change to be considered clinically mean-
ingful, though a more conservative MID suggested that a
change of >6.5-7 points would be needed.
In support of its divergent (or discriminant) validity,
and as expected, we were able to demonstrate that
responses to the SCI-R were largely unrelated to
measures of treatment satisfaction (DTSQ) and psycho-
logical well-being (W-BQ28). Known-groups validity was
partially supported. As expected, we found that those
with a lower HbA1c (≤7.5% (≤58 mmol/mol)) reported
greater engagement in self-care behaviours. We also
found that those with a longer duration of diabetes
(>16 years) reported greater engagement in self-care
behaviours overall. This finding may be due to the fact
that those individuals have had more time to adapt posi-
tively to living with diabetes. An alternative explanation
may be that increased self-care in those with a longer
duration is confounded with the development of
complications, increasing the individual’s perceived se-
verity of and susceptibility to negative outcomes and,
thus, increasing their engagement with self-care activ-
ities. However, we found no differences in total self-care
between those with and without complications or be-
tween the different insulin treatment algorithms.
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The current study offered the opportunity to establish
the psychometric properties of the SCI-R in a large
cross-sectional study of adults with type 2 diabetes to
the UK. While the analyses reported here offer prelimin-
ary evidence of validity and reliability, full psychometric
validation also involves assessment of test-retest relia-
bility, predictive validity and responsiveness, which
requires longitudinal data. This study is also limited by
the lack of opportunity for assessing the convergent val-
idity of the measures, i.e. the SCI-R was the only meas-
ure of diabetes self-care included in the study. It would
have been ideal to assess convergent validity by correlat-
ing SCI-R scores with scores on other instruments
measuring aspects of diabetes self-care, such as the
Summary of Diabetes Self-Care Activities (SDSCA) [8], a
measure of the frequency of performing diabetes self-
care tasks. Finally, this study was conducted using data
from the AT.LANTUS Follow-on study, which followed
up on approximately two-thirds of those in the original
AT.LANTUS trial. While the demographics and clinical
characteristics of those in our sample were similar to
those at the end of the original trial, those who agreed
to participate in the AT.LANTUS Follow-on study may
well have been more likely to follow their recommended
treatments, hence contributing to the ceiling effects
observed here.
Conclusions
Notwithstanding the limitations mentioned above, the
findings from the present study provide important
insights into the suitability of the SCI-R in people with
T2DM in the UK, with implications for clinical practice
and research. They also extend previous observations
[13] regarding the psychometric properties of the SCI-R.
Ceiling effects raise concerns about the potential of the
SCI-R for responsiveness in clinical trials but this is
likely to be true of other measures of self-care, all of
which are prone to social desirability bias. Perhaps, more
important is the issue of whether or not the SCI-R items
should be summed to form a total scale. On the basis of
the findings from the present study, and corroborating
the US validation [13], we recommend that analysis
involves scoring of individual items as well as the total
score. Analysis of data from the AT.LANTUS Follow-on
trial has demonstrated that the SCI-R is a valid and reli-
able measure of diabetes self-care and is suitable for use
in people with T2DM in the UK.Additional file
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